The complaint alleges that Phreesia executives issued misleading statements to the market while concealing material weaknesses in pharmaceutical marketing commitments. These internal issues culminated on March 30, 2026, when the company slashed its fiscal year 2027 revenue guidance, citing macroeconomic headwinds and poor visibility. The market response was immediate: Phreesia stock plummeted from $11.41 to $8.38 per share, representing a single-day decline of approximately 27 percent.

The Gross Law Firm is currently organizing the class action to recover losses incurred by shareholders during the period of alleged artificial price inflation. Participation in the lawsuit does not require appointment as a lead plaintiff, and registration provides investors with ongoing portfolio monitoring. Interested parties may submit their information through the firm’s online portal to receive updates on the case lifecycle at no cost.